Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded to “Hold” at StockNews.com

StockNews.com downgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a buy rating to a hold rating in a research note published on Monday morning.

Separately, HC Wainwright reaffirmed a neutral rating on shares of Oramed Pharmaceuticals in a research note on Monday, September 9th.

Oramed Pharmaceuticals Price Performance

Shares of NASDAQ:ORMP opened at $2.38 on Monday. The business’s 50 day moving average price is $2.39 and its 200-day moving average price is $2.41. The firm has a market capitalization of $96.70 million, a PE ratio of 9.15 and a beta of 1.77. Oramed Pharmaceuticals has a 1 year low of $1.67 and a 1 year high of $3.67.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.21. As a group, analysts expect that Oramed Pharmaceuticals will post 0.24 earnings per share for the current year.

Hedge Funds Weigh In On Oramed Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ORMP. XTX Topco Ltd purchased a new stake in Oramed Pharmaceuticals in the second quarter valued at $40,000. Virtu Financial LLC purchased a new stake in Oramed Pharmaceuticals in the first quarter valued at $68,000. Dimensional Fund Advisors LP raised its position in Oramed Pharmaceuticals by 52.1% in the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 10,774 shares during the period. Renaissance Technologies LLC raised its position in Oramed Pharmaceuticals by 89.0% in the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after purchasing an additional 108,700 shares during the period. Finally, Murchinson Ltd. raised its position in Oramed Pharmaceuticals by 31.4% in the first quarter. Murchinson Ltd. now owns 1,379,495 shares of the biotechnology company’s stock valued at $4,028,000 after purchasing an additional 329,495 shares during the period. Institutional investors and hedge funds own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.